Vaccitech’s $168M round to fund clinical work on three vaccines using heterologous prime-boost platform

U.K.-based Vaccitech will put its $168 million series B round toward clinical testing of three infectious disease and cancer programs that each use two different vectors for prime-boost delivery, while partner AstraZeneca markets and distributes the COVID-19 vaccine that uses one of the vectors.

An affiliate of M&G plc led the round, while Tencent, Gilead Sciences Inc. (NASDAQ:GILD), Monaco Constitutional Reserve Fund, and Future Planet Capital also participated...